1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Cardiac Resynchronization Therapy Systems Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Cardiac Resynchronization Therapy Systems Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Cardiac Resynchronization Therapy Systems Market Analysis and Forecast, by Product Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product Type, 2017–2031
6.3.1. Cardiac Resynchronization Therapy Pacemaker
6.3.2. Cardiac Resynchronization Therapy Defibrillator
6.4. Market Attractiveness Analysis, by Product Type
7. Global Cardiac Resynchronization Therapy Systems Market Analysis and Forecast, by Region
7.1. Key Findings
7.2. Market Value Forecast, by Region, 2017–2031
7.2.1. North America
7.2.2. Europe
7.2.3. Asia Pacific
7.2.4. Latin America
7.2.5. Middle East & Africa
7.3. Market Attractiveness Analysis, by Region
8. North America Cardiac Resynchronization Therapy Systems Market Analysis and Forecast
8.1. Introduction
8.2. Key Findings
8.3. Market Value Forecast, by Product Type, 2017–2031
8.3.1. Cardiac Resynchronization Therapy Pacemaker
8.3.2. Cardiac Resynchronization Therapy Defibrillator
8.4. Market Value Forecast, by Country, 2017–2031
8.4.1. U.S.
8.4.2. Canada
8.5. Market Attractiveness Analysis
8.5.1. By Product Type
8.5.2. By Country
9. Europe Cardiac Resynchronization Therapy Systems Market Analysis and Forecast
9.1. Introduction
9.2. Key Findings
9.3. Market Value Forecast, by Product Type, 2017–2031
9.3.1. Cardiac Resynchronization Therapy Pacemaker
9.3.2. Cardiac Resynchronization Therapy Defibrillator
9.4. Market Value Forecast, by Country/Sub-region, 2017–2031
9.4.1. Germany
9.4.2. U.K.
9.4.3. France
9.4.4. Italy
9.4.5. Spain
9.4.6. Rest of Europe
9.5. Market Attractiveness Analysis
9.5.1. By Product Type
9.5.2. By Country/Sub-region
10. Asia Pacific Cardiac Resynchronization Therapy Systems Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Product Type, 2017–2031
10.3.1. Cardiac Resynchronization Therapy Pacemaker
10.3.2. Cardiac Resynchronization Therapy Defibrillator
10.4. Market Value Forecast, by Country/Sub-region, 2017–2031
10.4.1. China
10.4.2. Japan
10.4.3. India
10.4.4. Australia & New Zealand
10.4.5. Rest of Asia Pacific
10.5. Market Attractiveness Analysis
10.5.1. By Product Type
10.5.2. By Country/Sub-region
11. Latin America Cardiac Resynchronization Therapy Systems Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Product Type, 2017–2031
11.3.1. Cardiac Resynchronization Therapy Pacemaker
11.3.2. Cardiac Resynchronization Therapy Defibrillator
11.4. Market Value Forecast, by Country/Sub-region, 2017–2031
11.4.1. Brazil
11.4.2. Mexico
11.4.3. Rest of Latin America
11.5. Market Attractiveness Analysis
11.5.1. By Product Type
11.5.2. By Country/Sub-region
12. Middle East & Africa Cardiac Resynchronization Therapy Systems Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Product Type, 2017–2031
12.3.1. Cardiac Resynchronization Therapy Pacemaker
12.3.2. Cardiac Resynchronization Therapy Defibrillator
12.4. Market Value Forecast, by Country/Sub-region, 2017–2031
12.4.1. GCC Countries
12.4.2. South Africa
12.4.3. Rest of Middle East & Africa
12.5. Market Attractiveness Analysis
12.5.1. By Product Type
12.5.2. By Country/Sub-region
13. Competition Landscape
13.1. Market Player – Competitive Matrix (by Tier and Size of Companies)
13.2. Market Share Analysis, by Company (2022)
13.3. Company Profiles
13.3.1. Medtronic
13.3.1.1. Company Overview
13.3.1.2. Product Portfolio
13.3.1.3. SWOT Analysis
13.3.1.4. Financial Overview
13.3.1.5. Strategic Overview
13.3.2. Boston Scientific Corporation
13.3.2.1. Company Overview
13.3.2.2. Product Portfolio
13.3.2.3. SWOT Analysis
13.3.2.4. Financial Overview
13.3.2.5. Strategic Overview
13.3.3. Abbott
13.3.3.1. Company Overview
13.3.3.2. Product Portfolio
13.3.3.3. SWOT Analysis
13.3.3.4. Financial Overview
13.3.3.5. Strategic Overview
13.3.4. LivaNova PLC
13.3.4.1. Company Overview
13.3.4.2. Product Portfolio
13.3.4.3. SWOT Analysis
13.3.4.4. Financial Overview
13.3.4.5. Strategic Overview
13.3.5. BIOTRONIK SE & Co. KG
13.3.5.1. Company Overview
13.3.5.2. Product Portfolio
13.3.5.3. SWOT Analysis
13.3.5.4. Financial Overview
13.3.5.5. Strategic Overview
13.3.6. Asahi Kasei Medical Co., Ltd.
13.3.6.1. Company Overview
13.3.6.2. Product Portfolio
13.3.6.3. SWOT Analysis
13.3.6.4. Financial Overview
13.3.6.5. Strategic Overview
13.3.7. NIHON KOHDEN CORPORATION
13.3.7.1. Company Overview
13.3.7.2. Product Portfolio
13.3.7.3. SWOT Analysis
13.3.7.4. Financial Overview
13.3.7.5. Strategic Overview
13.3.8. Schiller AG
13.3.8.1. Company Overview
13.3.8.2. Product Portfolio
13.3.8.3. SWOT Analysis
13.3.8.4. Financial Overview
13.3.8.5. Strategic Overview
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
